There is new hope for epileptics whose seizures are not controlled with medication. The FDA recently gave pre-market approval to the NeuroPace System, a responsive neurostimulator device that works to detect abnormal brain activity and respond by delivering imperceptible levels of electrical stimulation to normalize brain activity before an individual experiences seizures.
Erick Gordon knows better than most the impact this device approval can have on people with epilepsy. Erick participated in the clinical trial of the device at MUSC and has seen dramatic improvements in his quality of life.
To learn more about the NeuroPace System, how it changed Erick’s life, and why Dr. Jonathan Edwards, Director of the Comprehensive Epilepsy Center is so excited about this FDA approval and it’s possibilities for people not only with epilepsy but potentially other neurological disorders in the future visit the MUSC Newsroom.